For the quarter ending 2025-09-30, DNTH made $396K in revenue. -$36,700K in net income. Net profit margin of -9267.68%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 396 | 193 | 1,163 | 2,172 |
| Research and development | 32,489 | 26,251 | 27,003 | 25,544 |
| General and administrative | 8,195 | 8,869 | 7,337 | 6,528 |
| Total operating expenses | 40,684 | 35,120 | 34,340 | 32,072 |
| Loss from operations | -40,288 | -34,927 | -33,177 | -29,900 |
| Interest and investment income | 3,658 | 3,403 | 3,791 | - |
| Gain on investment in former related party | 227 | 32 | - | - |
| Loss on currency exchange, net | -2 | -30 | -22 | -48 |
| Gain on investment in related party | - | - | - | 307 |
| Interest income, other | - | - | - | 4,445 |
| Loss on investment in related party | - | - | 5 | - |
| Other (expense)/income | -360 | -107 | -98 | 22 |
| Total other income | 3,523 | 3,298 | 3,666 | 4,726 |
| Net loss | -36,765 | -31,629 | -29,511 | -25,174 |
| Unrealized gain on marketable securities | 65 | -172 | 164 | 718 |
| Total other comprehensive income | 65 | -172 | 164 | 718 |
| Total comprehensive loss | -36,700 | -31,801 | -29,347 | -24,456 |
| Net loss per share attributable to common stockholders, basic | -0.97 | -0.88 | -0.82 | -0.74 |
| Net loss per share attributable to common stockholders, diluted | -0.97 | -0.88 | -0.82 | -0.74 |
| Weighted-average number of shares of common stock outstanding including shares issuable under equity-classified pre-funded warrants, used in computing net loss per share of common stock, basic | 37,794,088 | 35,822,308 | 35,790,700 | 34,236,728 |
| Weighted-average number of shares of common stock outstanding including shares issuable under equity-classified pre-funded warrants, used in computing net loss per share of common stock, diluted | 37,794,088 | 35,822,308 | 35,790,700 | 34,236,728 |
Dianthus Therapeutics, Inc. DE (DNTH)
Dianthus Therapeutics, Inc. DE (DNTH)